Tripelennamine
From Wikipedia, the free encyclopedia
| Image:Tripelennamine.png | |
|
Tripelennamine
|
|
| Systematic (IUPAC) name | |
| N-benzyl-N',N'-dimethyl-N- pyridin-2-yl-ethane-1,2-diamine | |
| Identifiers | |
| CAS number | 91-81-6 |
| ATC code | D04AA04 R06AC04 |
| PubChem | 5587 |
| DrugBank | APRD00689 |
| Chemical data | |
| Formula | C16H21N3 |
| Mol. weight | 255.358 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tripelennamine is a pyridine antipruritic and antihistamine. It is a first-generation antihistamine in the class of ethylenediamines and is marketed by Novartis under the trade name Pyribenzamine.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
